Implant Sciences Ships $750,000 of Explosives Trace Detector Systems to Asia

Systems to be deployed for military, aviation security, and critical infrastructure protection

Mar 23, 2015, 07:00 ET from Implant Sciences Corporation

WILMINGTON, Mass., March 23, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today reported the shipment of more than $750,000 in explosives trace detection systems to various customers in Asia. The shipments include a mixture of QS-H150 and QS-B220 systems, and will be deployed in military, aviation security, and critical infrastructure protection applications.

"Asia continues to remain a strong market for the company, and our certification successes have helped build our sales in the region even more. Our year-to-date shipments to Asian customers for FY2015 already exceed all of last year, and we have additional opportunities in the pipeline," stated Dr. Darryl Jones, Implant Sciences' Global Vice President of Sales and Marketing.

"The mix of new and repeat customers validates Implant Sciences as a market leader and technology innovator," said Dr. Jones.  "We look forward to continuing to build our market presence in Asia."

About the QS-B220 Desktop Explosives and Drugs Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as illicit drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About the QS-H150 Handheld Explosives Trace Detector

The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 50 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the GSN Homeland Security Award for "Best Explosives Detection Solution" two years in a row (2013 and 2014).  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at

Cautionary Note Regarding Forward-Looking Statements

This press release and any related statements of management and representatives of Implant Sciences Corporation (the "Company") contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that the Company will be required to repay all of its indebtedness to secured lenders by the due dates; the risk that if the Company is unable to satisfy its obligations to its secured lenders and to raise additional capital to fund operations, lenders may seize the Company's assets and its business may fail; the Company continues to incur substantial operating losses and may never generate recurring revenue or profitability; the Company's independent registered public accounting firm has expressed substantial doubt as to the Company's ability to continue as a going concern; there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of the Company's explosives detection products or that any new products which the Company may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect the Company's sales; liability claims related to the Company's products or the Company's handling of hazardous materials could damage the Company's reputation and have a material adverse effect on the Company's financial results; the Company's business is subject to intense competition; the Company's markets are subject to rapid technology change and the Company's viability will depend on its ability to develop and introduce new products; the Company may not be able to retain its management and key employees or identify, hire and retain additional personnel as needed; the Company may not be able to enforce its patent and other intellectual property rights or operate without infringing on the proprietary rights of others; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could cause the actual results to differ materially from those anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 


Implant Sciences Corporation
Company Contact:
978-752-1700 x 116   


Investor Contact:
Laurel Moody

SOURCE Implant Sciences Corporation